Hugel reported record first-half revenue of ₩254.5 billion (approximately $195M USD) with operating profit of ₩103.7 billion, powered by accelerating overseas sales of its BOTULAX and DERMALINE toxin and filler lines. The company's international footprint—particularly in Southeast Asia, the Middle East, and emerging markets—is now the primary growth engine, offsetting domestic market saturation in Korea.
Market
Hugel Posts Record H1 Revenue on Overseas Toxin Surge
South Korea's largest injectable maker hits ₩254.5B revenue, driven by international expansion.
Record ₩254.5B H1 revenue driven by overseas toxin and filler growth.
Context: Hugel's scale and manufacturing efficiency give it pricing power in price-sensitive markets where U.S. practices source gray-market supply. The company's overseas momentum also signals that Korean toxins are consolidating shelf space in regions where European and U.S. brands once dominated. For practices tracking cost-of-goods trends, Hugel's profitability at scale suggests Korean manufacturers will remain aggressive on wholesale pricing.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.